Seaport Therapeutics CEO Daphne Zohar at the Endpoints 11 gala (Michael Last Photography)
October 21, 2024 02:00 AM EDTUpdated 04:52 AM
Financing
Startups

For­mer Karuna crew quick­ly as­sem­bles $225M for next neu­ro bet at Sea­port

Kyle LaHucik

Senior Reporter

The team at Sea­port Ther­a­peu­tics, a Boston neu­ropsy­chi­a­try biotech, is hav­ing a good fall sea­son.

Sea­port said Mon­day it has pieced to­geth­er $225 mil­lion from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times